BioNexus Gene Lab Corp. (BGLC) Free cash flow 2018–2025
BioNexus Gene Lab Corp. (BGLC) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$1.9MFY2025 · since FY2018: -$313,701 → -$1.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$1.9M | +19.2% |
| FY2024 | -$2.3M | -17.7% |
| FY2023 | -$2.0M | -457.3% |
| FY2022 | $551,822 | +9098.6% |
| FY2021 | $5,999 | -95.4% |
| FY2020 | $131,059 | +157.0% |
| FY2019 | -$230,090 | +26.7% |
| FY2018 | -$313,701 | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BGLC financial trends
BGLC RevenueBGLC Net incomeBGLC Net marginBGLC Gross profitBGLC Gross marginBGLC Operating incomeBGLC Operating marginBGLC Operating cash flowBGLC Capital expendituresBGLC Return on equityBGLC Stock buybacksBGLC Dividends paidBGLC Total assetsBGLC Total liabilitiesBGLC Shareholders’ equityBGLC overview →